{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T21:27:29Z","timestamp":1744752449963,"version":"3.37.3"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s11523-023-01009-w","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T10:02:30Z","timestamp":1699005750000},"page":"927-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2167-7893","authenticated-orcid":false,"given":"Marine","family":"Marchal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Behal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Dansin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Bordier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Humez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Escande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Gauvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis B.","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"1009_CR1","unstructured":"Clinical Practice Living Guidelines\u2014Metastatic Non-Small-Cell Lung Cancer | ESMO, (n.d.). https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/lung-and-chest-tumours\/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer. Accessed 6 Aug 2022."},{"key":"1009_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.363","author":"G de Castro","year":"2021","unstructured":"de Castro G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1\u2013positive, locally advanced or metastatic non\u2013small-cell lung cancer. J Immunother Cancer. 2021;9:363. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.363.","journal-title":"J Immunother Cancer."},{"key":"1009_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Five-year outcomes from the randomized, phase III Trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39:723\u201333. https:\/\/doi.org\/10.1200\/JCO.20.01605.","journal-title":"J Clin Oncol"},{"key":"1009_CR4","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","volume":"126","author":"H Li","year":"2022","unstructured":"Li H, van der Merwe PA, Sivakumar S. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022;126:1663\u201375. https:\/\/doi.org\/10.1038\/s41416-022-01743-4.","journal-title":"Br J Cancer"},{"key":"1009_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2014a meta-analysis. J Thorac Oncol. 2017;12:403\u20137. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.007.","journal-title":"J Thorac Oncol"},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","volume":"13","author":"A Lisberg","year":"2018","unstructured":"Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138\u201345. https:\/\/doi.org\/10.1016\/j.jtho.2018.03.035.","journal-title":"J Thorac Oncol."},{"key":"1009_CR7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz167.","journal-title":"Ann Oncol"},{"key":"1009_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002891","volume":"9","author":"MV Negrao","year":"2021","unstructured":"Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021;9: e002891. https:\/\/doi.org\/10.1136\/jitc-2021-002891.","journal-title":"J Immunother Cancer"},{"key":"1009_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356145","volume":"6","author":"Z-Y Dong","year":"2017","unstructured":"Dong Z-Y, Zhang J-T, Liu S-Y, Su J, Zhang C, Xie Z, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. OncoImmunology. 2017;6: e1356145. https:\/\/doi.org\/10.1080\/2162402X.2017.1356145.","journal-title":"OncoImmunology."},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3101.","journal-title":"Clin Cancer Res"},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.canlet.2019.10.027","volume":"470","author":"C Liu","year":"2020","unstructured":"Liu C, Zheng S, Jin R, Wang X, Wang F, Zang R, et al. The superior efficacy of anti-PD-1\/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2020;470:95\u2013105. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.027.","journal-title":"Cancer Lett"},{"key":"1009_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.3390\/jcm9072093","volume":"9","author":"J Garc\u00eda-Gonz\u00e1lez","year":"2020","unstructured":"Garc\u00eda-Gonz\u00e1lez J, Ruiz-Ba\u00f1obre J, Afonso-Afonso FJ, Amenedo-Gancedo M, Areses-Manrique MC, Campos-Balea B, et al. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: a pairwise meta-analysis. J Clin Med. 2020;9:2093. https:\/\/doi.org\/10.3390\/jcm9072093.","journal-title":"J Clin Med"},{"key":"1009_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0099.","journal-title":"Cancer Discov"},{"key":"1009_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","volume":"8","author":"R Bai","year":"2020","unstructured":"Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8:34. https:\/\/doi.org\/10.1186\/s40364-020-00209-0.","journal-title":"Biomark Res."},{"key":"1009_CR15","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1801005.","journal-title":"N Engl J Med"},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21:15\u201325. https:\/\/doi.org\/10.1038\/cdd.2013.67.","journal-title":"Cell Death Differ"},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"key":"1009_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138245","volume":"10","author":"N D\u2019Haene","year":"2015","unstructured":"D\u2019Haene N, Le Mercier M, De N\u00e8ve N, Blanchard O, Delaunoy M, El Housni H, et al. Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS ONE. 2015;10: e0138245. https:\/\/doi.org\/10.1371\/journal.pone.0138245.","journal-title":"PLoS ONE"},{"key":"1009_CR19","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.jtho.2018.08.2023","volume":"13","author":"C Descarpentries","year":"2018","unstructured":"Descarpentries C, Lepr\u00eatre F, Escande F, Kherrouche Z, Figeac M, Sebda S, et al. Optimization of routine testing for MET exon 14 splice site mutations in NSCLC patients. J Thorac Oncol. 2018;13:1873\u201383. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2023.","journal-title":"J Thorac Oncol"},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","volume":"31","author":"DR Spigel","year":"2013","unstructured":"Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non\u2013small-cell lung cancer. JCO. 2013;31:4105\u201314. https:\/\/doi.org\/10.1200\/JCO.2012.47.4189.","journal-title":"JCO"},{"key":"1009_CR21","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.1016\/j.cllc.2020.11.002","volume":"22","author":"W Yin","year":"2021","unstructured":"Yin W, Cheng J, Tang Z, Toruner G, Hu S, Guo M, et al. MET amplification (MET\/CEP7 ratio \u2265 1.8) is an independent poor prognostic marker in patients with treatment-naive non\u2013small-cell lung cancer. Clin Lung Cancer. 2021;22:e512\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2020.11.002.","journal-title":"Clin Lung Cancer"},{"key":"1009_CR22","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/jcm12051833","volume":"12","author":"M Montrone","year":"2023","unstructured":"Montrone M, Rosati G, Longo V, Catino A, Massafra R, Nardone A, et al. Immunotherapy in elderly patients affected by non-small cell lung cancer: a narrative review. J Clin Med. 2023;12:1833. https:\/\/doi.org\/10.3390\/jcm12051833.","journal-title":"J Clin Med"},{"key":"1009_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100265","volume":"3","author":"D Fujimoto","year":"2022","unstructured":"Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, et al. A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC. JTO Clin Res Rep. 2022;3: 100265. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100265.","journal-title":"JTO Clin Res Rep."},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","volume":"28","author":"H Hayashi","year":"2022","unstructured":"Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, et al. A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L). Clin Cancer Res. 2022;28:893\u2013902. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3194.","journal-title":"Clin Cancer Res"},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.lungcan.2012.10.002","volume":"79","author":"HY Lee","year":"2013","unstructured":"Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han J-H, Sun J-M, et al. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer. 2013;79:40\u20135. https:\/\/doi.org\/10.1016\/j.lungcan.2012.10.002.","journal-title":"Lung Cancer"},{"key":"1009_CR26","doi-asserted-by":"publisher","first-page":"16122","DOI":"10.1038\/s41598-021-95628-w","volume":"11","author":"C-I Shen","year":"2021","unstructured":"Shen C-I, Chao H-S, Shiao T-H, Chiang C-L, Huang H-C, Luo Y-H, et al. Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Sci Rep. 2021;11:16122. https:\/\/doi.org\/10.1038\/s41598-021-95628-w.","journal-title":"Sci Rep"},{"key":"1009_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100427","volume":"3","author":"DJ Benjamin","year":"2022","unstructured":"Benjamin DJ, Chen S, Eldredge JB, Schokrpur S, Li D, Quan Z, et al. The role of chemotherapy plus immune checkpoint inhibitors in oncogenic-driven NSCLC: a university of California lung cancer consortium retrospective study. JTO Clin Res Rep. 2022;3: 100427. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100427.","journal-title":"JTO Clin Res Rep."},{"key":"1009_CR28","doi-asserted-by":"publisher","unstructured":"Yang JC-H, Lee DH, Lee J-S, Fan Y, De Marinis F, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study. JCO. 2023;41:LBA9000\u2013LBA9000. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA9000.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9000"},{"key":"1009_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00135-2","author":"S Lu","year":"2023","unstructured":"Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624-636. https:\/\/doi.org\/10.1016\/S2213-2600(23)00135-2.","journal-title":"Lancet Respir Med"},{"key":"1009_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.014","volume":"183","author":"O Bylicki","year":"2023","unstructured":"Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Decroisette C, Greillier L. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: a multicentre phase II open-label non-randomised study GFPC 06-2018. Eur J Cancer. 2023;183:38\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2023.01.014.","journal-title":"Eur J Cancer."},{"key":"1009_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","volume":"7","author":"M Reck","year":"2019","unstructured":"Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387\u2013401. https:\/\/doi.org\/10.1016\/S2213-2600(19)30084-0.","journal-title":"Lancet Respir Med"},{"key":"1009_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860313","author":"X Yu","year":"2022","unstructured":"Yu X, Ji X, Su C. HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies. Front Oncol. 2022;12:860313. https:\/\/doi.org\/10.3389\/fonc.2022.860313.","journal-title":"Front Oncol"},{"key":"1009_CR33","doi-asserted-by":"publisher","first-page":"175883592210823","DOI":"10.1177\/17588359221082339","volume":"14","author":"G Yang","year":"2022","unstructured":"Yang G, Yang Y, Liu R, Li W, Xu H, Hao X, et al. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study. Ther Adv Med Oncol. 2022;14:17588359221082340. https:\/\/doi.org\/10.1177\/17588359221082339.","journal-title":"Ther Adv Med Oncol."},{"key":"1009_CR34","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.jtho.2021.06.025","volume":"16","author":"FC Saalfeld","year":"2021","unstructured":"Saalfeld FC, Wenzel C, Christopoulos P, Merkelbach-Bruse S, Reissig TM, La\u00dfmann S, et al. National network genomic medicine lung cancer (nNGM), efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations. J Thorac Oncol. 2021;16:1952\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.025.","journal-title":"J Thorac Oncol"},{"key":"1009_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634920","volume":"11","author":"X Niu","year":"2021","unstructured":"Niu X, Sun Y, Planchard D, Chiu L, Bai J, Ai X, et al. Durable response to the combination of atezolizumab with platinum-based chemotherapy in an untreated non-smoking lung adenocarcinoma patient with BRAF V600E mutation: a case report. Front Oncol. 2021;11: 634920. https:\/\/doi.org\/10.3389\/fonc.2021.634920.","journal-title":"Front Oncol"},{"key":"1009_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.750657","volume":"11","author":"K Seegobin","year":"2021","unstructured":"Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in non-small cell lung cancer with actionable mutations other than EGFR. Front Oncol. 2021;11: 750657. https:\/\/doi.org\/10.3389\/fonc.2021.750657.","journal-title":"Front Oncol"},{"key":"1009_CR37","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.ccr-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, et al. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer. Clin Cancer Res. 2018;24:4579\u201387. https:\/\/doi.org\/10.1158\/1078-0432.ccr-18-0267.","journal-title":"Clin Cancer Res"},{"key":"1009_CR38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fonc.2020.00054","volume":"10","author":"HF Titmarsh","year":"2020","unstructured":"Titmarsh HF, O\u2019Connor R, Dhaliwal K, Akram AR. The emerging role of the c-MET-HGF axis in non-small cell lung cancer tumor immunology and immunotherapy. Front Oncol. 2020;10:54. https:\/\/doi.org\/10.3389\/fonc.2020.00054.","journal-title":"Front Oncol"},{"key":"1009_CR39","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lungcan.2021.08.015","volume":"161","author":"K Morimoto","year":"2021","unstructured":"Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, et al. Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Lung Cancer. 2021;161:26\u201333. https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.015.","journal-title":"Lung Cancer"},{"key":"1009_CR40","doi-asserted-by":"publisher","first-page":"48248","DOI":"10.18632\/oncotarget.17594","volume":"8","author":"JH Kim","year":"2017","unstructured":"Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review. Oncotarget. 2017;8:48248\u201352. https:\/\/doi.org\/10.18632\/oncotarget.17594.","journal-title":"Oncotarget"},{"key":"1009_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00262-021-03031-1","volume":"71","author":"T Landre","year":"2022","unstructured":"Landre T, Justeau G, Assi\u00e9 J-B, Chouahnia K, Davoine C, Taleb C, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71:719\u201326. https:\/\/doi.org\/10.1007\/s00262-021-03031-1.","journal-title":"Cancer Immunol Immunother"},{"key":"1009_CR42","doi-asserted-by":"publisher","unstructured":"Gadgeel S, Rodriguez-Abreu D, Felip E, Esteban E, Speranza G, Reck M, et al. LBA5-KRAS mutational status and efficacy in KEYNOTE-189: pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann Oncol. 2019;30:xi64\u2013xi65. https:\/\/doi.org\/10.1093\/annonc\/mdz453.002.","DOI":"10.1093\/annonc\/mdz453.002"},{"key":"1009_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003027","volume":"10","author":"HJ West","year":"2022","unstructured":"West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, et al. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022;10: e003027. https:\/\/doi.org\/10.1136\/jitc-2021-003027.","journal-title":"J Immunother Cancer"},{"key":"1009_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.08.011","volume":"157","author":"AD Federico","year":"2021","unstructured":"Federico AD, Giglio AD, Parisi C, Gelsomino F. STK11\/LKB1 and KEAP1 mutations in non-small cell lung cancer: prognostic rather than predictive? Eur J Cancer. 2021;157:108\u201313. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.011.","journal-title":"Eur J Cancer"},{"key":"1009_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.lungcan.2019.04.005","volume":"132","author":"S Assoun","year":"2019","unstructured":"Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, et al. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Lung Cancer. 2019;132:65\u201371. https:\/\/doi.org\/10.1016\/j.lungcan.2019.04.005.","journal-title":"Lung Cancer"},{"key":"1009_CR46","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"Z-Y Dong","year":"2017","unstructured":"Dong Z-Y, Zhong W-Z, Zhang X-C, Su J, Xie Z, Liu S-Y, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23:3012\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2554.","journal-title":"Clin Cancer Res"},{"key":"1009_CR47","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.prp.2016.05.006","volume":"212","author":"J-S Pyo","year":"2016","unstructured":"Pyo J-S, Kang G, Cho WJ, Choi SB. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: a meta-analysis. Pathol Res Pract. 2016;212:710\u20136. https:\/\/doi.org\/10.1016\/j.prp.2016.05.006.","journal-title":"Pathol Res Pract"},{"key":"1009_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.lungcan.2020.01.005","volume":"141","author":"K Yoshimura","year":"2020","unstructured":"Yoshimura K, Inoue Y, Tsuchiya K, Karayama M, Yamada H, Iwashita Y, et al. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer. Lung Cancer. 2020;141:21\u201331. https:\/\/doi.org\/10.1016\/j.lungcan.2020.01.005.","journal-title":"Lung Cancer"},{"key":"1009_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13000-015-0362-5","volume":"10","author":"I Watermann","year":"2015","unstructured":"Watermann I, Schmitt B, Stellmacher F, M\u00fcller J, Gaber R, Kugler C, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015;10:130. https:\/\/doi.org\/10.1186\/s13000-015-0362-5.","journal-title":"Diagn Pathol"},{"key":"1009_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","volume":"35","author":"DR Spigel","year":"2017","unstructured":"Spigel DR, Edelman MJ, O\u2019Byrne K, Paz-Ares L, Mocci S, Phan S, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol. 2017;35:412\u201320. https:\/\/doi.org\/10.1200\/JCO.2016.69.2160.","journal-title":"J Clin Oncol"},{"key":"1009_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","volume":"12","author":"A Drilon","year":"2017","unstructured":"Drilon A, Cappuzzo F, Ou S-HI, Camidge DR. Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol. 2017;12:15\u201326. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.014.","journal-title":"J Thorac Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01009-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-01009-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01009-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T09:20:27Z","timestamp":1700644827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-01009-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-01009-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"11 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.B.C. has received research grants (paid to institution) from Merck; consulting fees from Novartis and Roche; a speaker honorarium from Astra-Zeneca, BMS, MSD, Pfizer, Novartis, Takeda, Janssen, Roche, Abbvie, Amgen, and Exeliom; support from Pfizer, Novartis, and MSD to attend meetings; and has served on advisory boards for Novartis and InhaTarget. V.L. has received a speaker honorarium from Novartis, Astra-Zeneca and MSD. E.D. has received a speaker honorarium from Novartis. M.M., H.B., N.P., S.B., S.H., F.E., and G.C. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective, non-interventional study was conducted in compliance with GDPR (EU General Data Protection Regulation) and MR004 (Reference Methodology 004 for data protection) and was approved by the Data Protection Officer of GHT (Territorial Hospital Group) Lille M\u00e9tropole Flandre Int\u00e9rieure, registered under ID 865.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable due to the retrospective nature of the study. The patients were informed, by a mention in medical letters, of treatment of their data for research purposes. The local databases and medical files were searched for any potential refusal of additional data treatment.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors gave their consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M.M. and A.B.C. contributed to the study conception and design, data collection, and analyses. Statistical analyses were carried out by H.B. Early versions of the manuscript were drafted by M.M. and A.B.C. All authors provided feedback on the manuscript and have read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}